🤖 Introducing Owkin K: A community of specialized AI agents. Their mission? To work with our data scientists on decoding the complexities of the immune system. We are excited to continue our ambition for the future of drug discovery, development and diagnostics. 🚀 Watch the video to find out how Owkin will use agentic AI in the future. #ai #agenticai
Owkin
Biotechnology Research
New York, NY 41,490 followers
We use AI to find the right treatment for every patient.
About us
Owkin is an AI biotechnology company that uses AI to find the right treatment for every patient. We combine the best of human and artificial intelligence to answer the research questions shared by biopharma and academic researchers. By closing the translational gap between complex biology and new treatments, we bring new diagnostics and drugs to patients sooner. We use AI to identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools. Using federated learning, a pioneering collaborative AI framework, Owkin enables partners to unlock valuable insights from siloed datasets while protecting patient privacy and securing proprietary data. Owkin was co-founded by Thomas Clozel MD, a former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $300 million and became a unicorn through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).
- Website
-
https://www.owkin.com
External link for Owkin
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- New York, NY
- Type
- Privately Held
- Founded
- 2016
- Specialties
- artificial intelligence, omics technology, oncology, drug discovery, medical research, biomedical images, real-world data, real world evidence, radiology, clinical data, federated learning, covariate adjustment, clinical tools, digital pathology, healthcare, diagnostic solutions, biomarkers, precision medicine, and data science
Locations
Employees at Owkin
-
Jean-Philippe Vert
Chief R&D at Owkin / Co-founder at Bioptimus / Use AI to unravel biology and find the right treatment for every patient
-
Helen Burns
Freelance Resourcing Director | Talent Acquisition Leader | Coach delivering impact through change | Flow Game Host
-
Michaël Auffret
-
Rodney Hawkins
Updates
-
Meet us at the European Congress of Pathology in Florence, booth #88. Here are a few reasons to stop by and chat with us: ❇️ Discover our new integration with Roche's navify® 🪧 Learn about MSIntuit® CRC advancements and our e-poster 🤖 Ask for a demo to see our innovative tools in action 🎗️ Get an overview of our products: RlapsRisk® BC and TLS Detect We look forward to seeing you there! #ECP2024 #ESPCongress #Innovation #DigitalPathology #pathology
-
Roche announced today the expansion of its #digitalpathology open environment with the integration of more than 20 advanced #artificialintelligence (AI) algorithms from eight new collaborators, including Owkin’s AI algorithm for the screening of microsatellite stability in colorectal cancer. These strategic collaborations aim to support pathologists and scientists in #cancerresearch and diagnosis by leveraging cutting-edge AI technology. Read the press release to learn more: https://lnkd.in/dWhkmZx5
-
🇫🇷 Our Research Scientist, 李泓昊LI Honghao, will be speaking at a plenary session at the Joint DFH/UFA workshop on AI in Medicine: Optimized Trials with Machine Learning on ‘Federated External Control Arms’ next Thursday, September 12. Honghao will discuss how federated learning can scale real-world data access for external control arms. Learn more about the event: https://lnkd.in/edDp98tM
-
🚀 Innovation is in Owkin's DNA. Our employees are true creators, and several of them have turned their ideas into realities. Congratulations to former Owkinaute Mathieu Galtier and his newest venture, Entalpic, on their €8.5 million seed funding! We look forward to seeing what’s next in the world of climate tech.
Announcing Entalpic’s 8.5m€ seed round co-lead by Breega, Cathay Innovation and Felicis A few months ago, Mathieu Galtier (CEO), Victor Schmidt (CTO) and Alexandre Duval (CSO) launched Entalpic after several years building the technology within academia. To get to the next step of actual CO2 emission removal, we have launched a for-profit company intending to build an AI powerhouse for materials discovery. We are targeting industrial processes with large CO2 emissions and believe that we can contribute to the emergence of greener and cheaper alternatives. Electrocatalysis is our first focus. Our ambition is massive: generative AI will drive a new wave of discoveries in materials science and chemistry. But bringing the output of these combined technologies to market will be hard and we intend to be the best of both worlds. We are an “ML for science” company. We believe in the transformative power of technology and science, and our ambition is to make a positive difference in the climate crisis. Many thanks to Maximilien Bacot from Breega, Jacky Abitbol from Cathay Innovation and Gabriella G. from Felicis for their trust and support. This funding will help us: - Build a world-class team of ML engineers and materials scientists. - Run physical experiments (outsourced) to generate rich datasets. - Train large ML models to generate relevant catalyst candidates. If you want to know more about us, check our website at https://entalpic.ai/ It is just the beginning, but we could not have reached this step without the invaluable help of friends, colleagues, and institutions that have made us who we are today. It is time for public and heartfelt thanks: - To our advisors who have been challenging our ideas Yoshua Bengio, Thomas Wolf, Michal Valko, Xavier Bresson, Jean-Louis Quéguiner, Arnaud Robert, Jörg Weiser, Clémence Bellanger, Henri Delahaye,Théau Peronnin, Camille Marini, and Gilles Wainrib - To the institutions that have trained and educated us: Mines Paris - PSL, CentraleSupélec, École Polytechnique, Ecole normale supérieure, University of Warwick, Inria, UCL and Universite de Montreal. - To Owkin and its co-founders Thomas Clozel and Gilles Wainrib, which our CEO helped grow from tiny startup to AI unicorn, and which gave back so much to us in the form of learnings and friends. - To Mila - Quebec Artificial Intelligence Institute and 21st by CentraleSupélec who are accompanying us in the first steps of our journey With this funding, we feel emboldened that our vision is possible. Let’s get to work!
Entalpic - AI-driven materials discovery for more sustainable industries
entalpic.ai
-
Come see us at #ESMO2024! Stop by to meet the team at booth 511, Hall E to talk about our AI research in oncology, how we work with pharma clients to deliver new drugs and better clinical trials, and develop AI diagnostics. https://lnkd.in/eHk_6yxt #France2030
-
🚀 We’re excited to announce the release of GrAIdient 0.4.0, now with full support for running Large Language Models (LLMs) on Mac laptops. This update brings optimized performance for the top contenders: Mistral 7B, Llama2 7B, Llama3 8B and Gemma2 2B. If you’d like to learn more, check out the guide from Jean-François Reboud on running these LLMs on your Mac: https://lnkd.in/eAF6beqF
-
📑 Owkin Data Scientist Yann Rodriguez explains our poster presentation 1779P at #ESMO24. Stop by on Saturday, September 14, to learn how we developed deep learning-based models to accurately detect Tertiary Lymphoid Structures (TLS) on histology slides, and to evaluate TLS as a prognostic factor. Book a meeting at booth 511, Hall E: https://lnkd.in/eHk_6yxt #France2030
-
Meet us at World CB & CDx this week in Boston to discuss developing AI-powered Dx from digital pathology and learn how to partner with us to match patients to the right drugs from clinical trial to practice. https://lnkd.in/enNrkdZy
-
🎧 How can MSIntuit® CRC empower pathologists to streamline MSI testing for colorectal cancer with H&E slides? Hear our Lead Data Scientist, Rémy Dubois, explain our e-poster at #ECP2024. Rémy will present this poster, Abstract #2349, with Arnaud Fouillet, our Sr. Product Manager, Diagnostics, which will be available at the E-Poster terminals throughout the congress. Book a demo at booth #88: https://lnkd.in/edf8CX8J